GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics.
GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics.
Location:
Boston, Massachusetts US
Categories:
Synthetic Cells Tissues and Beyond
Founded in:
2020
Employee number:
1-10
Annual revenue: